Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology

Myelodysplastic Syndromes (MDS) Clinical Trials

A listing of Myelodysplastic Syndromes (MDS) medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

Filter by:

Phase:

Age:

Gender:

Location:

Display New/Updated only

 

First 1 2 3 4 Last 

California

Alta Bates Comprehensive Cancer Center
Berkeley California 94704

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

California Cancer Associates for Research and Excellence (cCARE)
Escondido California 92025

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Marin Oncology Associates
Greenbrae California 94904-2007

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

UCSD-Thornton Hospital
La Jolla California 44106-5000

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Colorado

Denver Colorado 80218

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Florida

Tampa Florida 33602

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Georgia

Phoebe Cancer Center of Phoebe Putney Memorial Hospital
Albany Georgia 31701

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Illinois

Robert H Lurie Comprehensive Cancer Center/ NW Univ
Chicago Illinois 60611

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

University of Chicago Medical Center
Chicago Illinois 60637

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Louisiana

Hematology and Oncology Specialists, LLC
Metairie Louisiana 70006

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Maryland

Baltimore Maryland 21231

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Massachusetts

UMASS Memorial Hospital
Worcester Massachusetts 1655

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Boston Massachusetts 02215

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Minnesota

Mayo Clinic - Rochester
Rochester Minnesota 55905

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Mississippi

Jackson Oncology Associates PLLC
Jackson Mississippi 39202

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Missouri

Kansas City VA Medical Center/University of Kansas Medical Center
Kansas City Missouri 64128

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Saint Luke's Cancer Institute
Kansas City Missouri 64111

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Nebraska

University of Nebraska Medical Center
Omaha Nebraska 68198-6805

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

New York

Mount Sinai Medical Center
New York New York 10029

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Lake Success New York 11020

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

New York New York 10032

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

North Carolina

Eastern Institute of Medical Sciences
Greenville North Carolina 27834

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

North Dakota

Ohio

University Hospitals of Cleveland Case Medical Center
Cleveland Ohio 44106-5000

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Cleveland Ohio 44195

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Oregon

Kaiser Permanente Northwest Oncology/Hematology
Portland Oregon 97227

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Pennsylvania

University of Pennsylvania
Philadelphia Pennsylvania 19104

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Tennessee

Nashville Tennessee 37203

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Texas

Brooke Army Medical Center Francis Street Medical Center
Fort Sam Houston Texas 78235-8200

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

MD Anderson Cancer Center The University of Texas
Houston Texas 77030

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Michael Debakey VA Medical Center
Houston Texas 77030

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Millenium Oncology
Houston Texas 77090

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Tyler Texas 75702

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Virginia

VA Commonwealth University Massey Cancer Center
Richmond Virginia 23298-0037

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Norfolk Virginia 23502

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Washington

Fred Hutchinson Cancer Research Center
Seattle Washington 98109-4417

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

View More ▼

Yakima Washington 98902

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

West Virginia

West Virginia University - Clinical Trials Research Unit
Morgantown West Virginia 26506

E2905: Randomized Phase III Trial Comparing the frequency of Major Erythroid Response to Treatment with Lenolidomide Alone and in Combination with Epoetin Alfa in Subjects with Low or Intermediate 1 Risk MDS and Symptomatic Anemia

Australia

Royal Adelaide Hospital
Adelaide International SA 5000

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Royal Prince Alfred Hospital, Sydney Cancer Centre
Camperdown International 2050

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

The Northern Hospital
Epping International 3076

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Frankston Hospital Oncology Research
Frankston International VIC 3199

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Cabrini Hospital
Malvern International 3144

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Haematoloy and Oncology Clinics of Australia
Milton International 4064

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Belgium

AZ Klina
Brasschaat International 2930

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

AZ Sint-Jan AV Brugge
Brugge International 8000

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Grand Hôpital de Charleroi
Charleroi International 6000

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

UZ Leuven
Leuven International 3000

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

Canada

Juravinski Cancer Centre
Hamilton International L8V 5C2

A Phase 3, Multicenter, Randomized, Double-Blind study to compare the efficacy and safety to oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with low red blood cells requiring transfusions and low platelets due to IPSS lower-risk Myledoysplastic Syndromes (MDS).

First 1 2 3 4 Last 

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic email notifications as soon as a clinical trial is posted in the medical category you're interested in.